Patents Assigned to Bristol-Myers Squibb Company
  • Patent number: 10662172
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 26, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Patent number: 10660877
    Abstract: Disclosed are compounds of Formula (I) N-oxide, or salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 26, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Michael A. Poss, Sreekantha Ratna Kumar, Shoshana L. Posy, David R. Tortolani, Brian K. Whiteley, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
  • Publication number: 20200157233
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: November 18, 2019
    Publication date: May 21, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Patent number: 10654860
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: May 19, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wu Yang, Peter W. Glunz, Rajeev S. Bhide, Kamalraj Thiyagarajan
  • Patent number: 10653791
    Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 19, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Mark J. Selby, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
  • Publication number: 20200148779
    Abstract: Modified IgG1 Fc domains having reduced binding to Fc-gamma-receptors are provided. Further provided are fusion polypeptides comprising a modified IgG1 Fc domain. An antibody polypeptide that specifically binds a human CD40 is provided, wherein the antibody polypeptides are fusions of a domain antibody (dAb) comprising a single VH domain and an Fc domain. The antibody polypeptides do not exhibit CD40 agonist activity, do not substantially activate immature dendritic cells, and have improved biophysical properties.
    Type: Application
    Filed: May 24, 2018
    Publication date: May 14, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Suzanne J. SUCHARD
  • Patent number: 10633354
    Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is —OH or —OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Marcoux, Hai-Yun Xiao, T. G. Murali Dhar, Alaric J. Dyckman
  • Patent number: 10633342
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Emily Charlotte Cherney, Weifang Shan, Liping Zhang, David K. Williams, Weiwei Guo, Audris Huang, James Aaron Balog
  • Patent number: 10633419
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Patent number: 10633339
    Abstract: There is described a ROR? modulator of the formula (I), or stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. Also provided are pharmaceutical compositions comprising the same. The compound of the invention may be useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: T. G. Murali Dhar, Zili Xiao, Michael G. Yang
  • Publication number: 20200123229
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 23, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jonathan DAVIS, Dasa LIPOVSEK, Ray CAMPHAUSEN
  • Patent number: 10617765
    Abstract: The present disclosure provides an additive system for use in protein PEGylation. The additive system includes p-aminobenzoic hydrazide used either alone or in combination with aromatic amines, such as 3,5-diaminobenzoic acid, or with ammonium salts such as ammonium chloride or ammonium acetate. The disclosed additive combination provides several benefits including increased reaction rates, higher yields and reduction in the aminoxy-PEG equivalents required to complete the conjugation reaction. Typical reactions can be run by combining the additive or additive system with a solution of a protein and aminoxy-PEG reagent. The solution is adjusted to pH 4 and held at 20-25° C. without stirring until completion, typically within 24 hours.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 14, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Matthew R. Hickey, Antonio Ramirez
  • Patent number: 10618903
    Abstract: Disclosed are compounds of Formula (I) Formula (I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, and pyrazolo[1,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: April 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: John V. Duncia, Daniel S. Gardner, John Hynes, John E. Macor, Natesan Murugesan, Joseph B. Santella, Hong Wu, Durgarao Kantheti, Satheesh Kesavan Nair, Venkatram Reddy Paidi, Sreekantha Ratna Kumar, Kandhasamy Sarkunam, Ramesh Kumar Sistla, Subba Rao Polimera
  • Patent number: 10617675
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David B. Frennesson, Piyasena Hewawasam, Omar D. Lopez, Van N. Nguyen, Mark G. Saulnier, Yong Tu, Alan Xiangdong Wang, Gan Wang, Ningning Xu, Roshan Yadavrao Nimje, Hasibur Rahaman, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell, Makonen Belema
  • Patent number: 10618967
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: April 14, 2020
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Publication number: 20200109204
    Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 9, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
  • Patent number: 10611776
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati De Lucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Patent number: 10604541
    Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 31, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Wei Meng, Mark Liu, Bei Wang, Rulin Zhao
  • Patent number: 10604556
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 31, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen
  • Patent number: RE47929
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang